Drugs in Dev. Neurology
Phase II
Cyprus 
Details : Axon is developing AADvac1 as a vaccine with the potential to halt the progression of tau pathology in Alzheimer's disease. AADvac1 is currently the most clinically-advanced tau immonotherapy in development.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 11, 2021
Axon Presented Positive Phase II Trial Results of AADvac1 at AAT-AD/PD 2020
Details : A highly significant impact on neurodegeneration was shown on brain proteins in plasma - Neurofilament Light Chain, and CSF - Tau and p-Tau, and Diffusion Tensor Imaging.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 04, 2020
24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 19, 2015
Reset All
